Dr. Berta will present on the power of physiologically relevant biological assays translating from early drug discovery to the clinic. Her talk will show specific examples of the benefits of implementing complex, multiparametric cellular assays on a large, industrial scale, along the drug discovery pipeline from target ID to identifying potential responder populations. For target ID using RNAi technology, multiparametric assays generate biological activity profiles that provide valuable insight into complex disease models. Combined with miniaturization technologies and sophisticated data analysis tools, Dr. Berta and her group have identified novel targets for several therapeutic areas which are now either at target validation stage or have progressed to lead ID.
Attendees will receive a review of the benefits of integrating complex assay technologies from the early discovery phase to late in the pipeline and insight of Merck’
GTCbio's 3rd Assay Development and Screening Technologies conference will provide attendees with critical information to utilize in the discovery and development of assays, while keeping them informed about the latest screening technologies for both high-throughput screening and high-content screening. Topics being covered include cell based assays, high throughput screening, high content screening, in vitro assays and screening, novel assay and screening technologies, and target validation. For more information visit www.gtcbio.com.
ABOUT GTCbio
Contact: GTCBIO , ,
